arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Cartesian Therapeutics, Inc.

RNAC

$6.81 ▼ -0.03 (-0.44%) at close

11 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Excellent

Bullish

auto_awesome

Analytical Summary

Cartesian Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $176.9M

Dividend Yield —

Revenue Growth -92.8% ↘

Op. Margin None

ROIC 106.1% ↘

FCF / Share $-3.06 ↘

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

11-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.80M

↓ -92.8% —

Net Income Profit after all expenses

$-130.30M

↓ -68.3% —

Operating Margin Operating profit as % of sales

-112.8%

↑ +66.1% —

FCF / Share Free cash flow per share

$-3.06

↓ -61.2% —

trending_up

Bullish Indicators

Return on Common Equity (%)Return on Common Equity (%) is in the top quartile

warning

Bearish Risks

No bearish risks detected.

Health Breakdown

Returns

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2015 10-K ↗	FY 2016 Dec 31, 2014 10-K ↗	FY 2015 Dec 31, 2013 10-K ↗
Revenue Growth YoY (%)	-92.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1260%)	49.6% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+521%)	-76.5% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1057%)	30.2% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+278%)	412.6% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+5058%)	148.6% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1757%)	639.4% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+7893%)	-85.0% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1162%)	97.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1122%)	—	—
EPS Growth YoY (%)	-12.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	91.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	67.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	44.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—
Net Income Growth YoY (%)	-68.3% Weak Weak Year-over-year change in net income	64.8% Excellent Excellent Year-over-year change in net income	N/M	N/M	62.7% Excellent ↑ Excellent Improving Year-over-year change in net income	-24.4% Weak ↑ Weak Improving Year-over-year change in net income	15.3% Good ↑ Good Improving Year-over-year change in net income	-159.5% Weak Weak Year-over-year change in net income	-95.5% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-61.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	80.9% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-45.9% Weak Weak Year-over-year change in free cash flow	57.8% Excellent Excellent Year-over-year change in free cash flow	N/M	N/M	—	—	—	—	—
Revenue CAGR 3Y (%)	-70.7% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-23.0% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	16.1% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	155.0% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	355.0% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	40.3% Excellent Excellent Compound annual revenue growth over 3 years	30.0% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-30.0% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	42.3% Excellent ↓ Excellent Declining Compound annual revenue growth over 5 years	95.8% Excellent ↑ Excellent Improving Compound annual revenue growth over 5 years	79.1% Excellent Excellent Compound annual revenue growth over 5 years	94.7% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2015 10-K ↗	FY 2016 Dec 31, 2014 10-K ↗	FY 2015 Dec 31, 2013 10-K ↗
Operating Margin (%) (%)	—	-112.8% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-852%)	-332.3% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2315%)	13.1% Fair ↑ Fair Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-13%)	-5.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-136%)	-342.4% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2382%)	—	—	-421.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2906%)	—	—
Effective Tax Rate (%) (%)	6.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.4% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	8.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.8% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-164.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
Profit Margin (%) (%)	—	-199.0% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1758%)	—	31.9% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+166%)	-30.2% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-352%)	-415.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3558%)	—	—	-418.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3590%)	-423.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3631%)	—
FCF Margin (%) (%)	—	-84.2% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-197.5% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-29.6% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-72.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	205.3% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—	—
FCF / Net Income (x)	0.61x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.42x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.23x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	-0.93x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	2.39x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-0.49x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.92x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2015 10-K ↗	FY 2016 Dec 31, 2014 10-K ↗	FY 2015 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	106.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	647.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	18.1% Excellent ↓ Excellent Declining Return earned on debt + equity capital invested Optimal: > 10%	15.8% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-53.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	315.6% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-624.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-93.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	17.2% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	13.9% Good Good Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-48.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-10.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-28.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	8.8% Fair ↑ Fair Improving Operating profit relative to total assets Optimal: > 10%	-2.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	—	-146.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-59.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	103.2% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+588%)	—	49.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+233%)	37.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+151%)	-114.1% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-860%)	—	—	-118.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-893%)	21.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+44%)	14.7% Fair Fair Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: At sector avg	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2015 10-K ↗	FY 2016 Dec 31, 2014 10-K ↗	FY 2015 Dec 31, 2013 10-K ↗
Interest Coverage (x)	—	—	-41.15x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	4.80x Fair ↑ Fair Improving Operating income divided by interest expense Optimal: > 5x	-1.62x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-36.52x Weak → Weak Stable Operating income divided by interest expense Optimal: > 5x	-34.53x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-43.52x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-26.69x Weak Weak Operating income divided by interest expense Optimal: > 5x	-27.90x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-125.14M	$-212.61M	$-76.91M	$-106.44M	$-114.06M	$-138.69M	$-89.89M	$-37.40M	$-32.34M	$-16.59M	$-8.06M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2015 10-K ↗	FY 2016 Dec 31, 2014 10-K ↗	FY 2015 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	$0.11	$2.25	$5.03	$22.98	$22.35	$4.92	$4.40	—	—	—	—
Basic EPS, GAAP (USD)	$-5.02	$-4.48	$-49.76	$7.21	$-6.61	$-20.42	$-36.64	—	—	—	—
Free Cash Flow per Share (USD)	$-3.06	$-1.90	$-9.93	$-6.81	$-16.15	$10.11	$-33.94	—	—	—	—
Book Value per Share (USD)	$-4.85	$-0.26	$-81.55	$18.41	$5.47	$-5.00	$5.54	$73.44	$-1.61K	—	—
Tangible Book Value per Share (USD)	$-6.70	$-2.13	$-90.47	$18.41	$5.47	$-5.00	$5.54	$73.44	$-1.61K	—	—
Basic Weighted Avg Shares (shares)	25.97M	17.28M	5.17M	4.82M	3.81M	3.37M	1.52M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2015 10-K ↗	FY 2016 Dec 31, 2014 10-K ↗	FY 2015 Dec 31, 2013 10-K ↗
Working Capital (USD)	$114.34M	$193.65M	$22.52M	$123.06M	$72.19M	$69.80M	—	$6.93M	$31.62M	—	—
Total Equity (USD)	$-126.24M	$-6.80M	$-440.18M	$93.83M	$22.52M	$-18.01M	$8.40M	$54.96M	$-116.49M	$-87.75M	$-69.46M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2015 10-K ↗	FY 2016 Dec 31, 2014 10-K ↗	FY 2015 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$2.80M	$38.91M	$26.00M	$110.78M	$85.08M	$16.60M	$6.68M	$903.00K	$6.01M	$3.04M	—
Depreciation Expense (USD)	$2.40M	$1.20M	$700.00K	$700.00K	$600.00K	$600.00K	$700.00K	$975.00K	$1.04M	$864.00K	—
Net Income, GAAP (USD)	$-130.30M	$-77.42M	$-219.71M	$35.38M	$-25.69M	$-68.88M	$-55.35M	$-65.34M	$-25.17M	$-12.88M	—
Operating Cash Flow (USD)	$-73.94M	$-23.67M	$-51.16M	$-31.63M	$-60.38M	$34.88M	$-51.44M	$-59.16M	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 11 years · 41 quarters

Cartesian Therapeutics, Inc.

Analytical Summary

11-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RNAC with peers